MedPath

Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Registration Number
NCT00353028
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the treatment of children and adolescents with depression or depressive state

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PPlacebo-
FFluvoxamine maleate-
Primary Outcome Measures
NameTimeMethod
the time of onset of 50% decrease from baseline in the Japanese Version of the Structured Interview Guide for the Hamilton Depression Rating Scale (JSIGH-D) 17-item total score8 weeks
Secondary Outcome Measures
NameTimeMethod
The Clinical Global Impression(CGI) improvement at Week 88 weeks

Trial Locations

Locations (25)

S114.3.117 Kohnodai Hospital, National Center of N

🇯🇵

Chiba prefecture, Japan

S114.3.117 Fukuoka University Hospital

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Hatakeyama Clinic

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Kaname Clinic

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Kashi shinryo Clinic

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Kashii Sanatorium

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Kyushu University Hospital

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Shiranui Hospital

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Sugahara Tenjin Hospital

🇯🇵

Fukuoka prefecture, Japan

S114.3.117 Hiroshima-city Funairi Hospital

🇯🇵

Hiroshima prefecture, Japan

Scroll for more (15 remaining)
S114.3.117 Kohnodai Hospital, National Center of N
🇯🇵Chiba prefecture, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.